Search

The clinical Impact of the association between oral contraceptive (OC) use and breast cancer risk is important given that OCs are the most commonly prescribed contraceptive agent and that more [...]

OBJECTIVE: To estimate the association between antioxidant use and primary cancer Incidence and mortality and to evaluate these effects across specific antioxidant compounds, target organs, and participant subgroups. METHODS: Multiple [...]

The author reflects on the association of the oral contraceptive usage to breast cancer risks. The author emphasized the from the perspective of epidemiology and public health, the proper handling of the epidemiology of oral contraceptives use and health outcomes in both a beneficial and a deleterious manner should be followed. The identification of modifiable factors before first full-term pregnancy would support the window for breast cancer prevention to earlier in life.

The clinical impact of the association between oral contraceptive (OC) use and breast cancer risk is important given that OCs are the most commonly prescribed contraceptive agent and that more than a quarter of a million women are diagnosed as having breast cancer in the United States annually. Substantial changes to OC formulations have been made during the past decade, and this review focuses on recent OC trends and risks and benefits. We also have a better understanding of how estrogen affects breast carcinogenesis; research on this topic is ongoing and has the goal of decreasing breast cancer incidence and mortality. [ABSTRACT FROM AUTHOR]

A letter to the editor is presented in response to the article "Oral Contraceptive Use and the Risk of Breast Cancer," by Petra M. Casey, J. R. Cerhan and S. Pruthi in the 2008 issue.

Objective: To report the Mayo Clinic experience with coronavirus disease 2019 (COVID-19) related to patient outcomes., Methods: We conducted a retrospective chart review of patients with COVID-19 diagnosed between March 1, 2020, and July 31, 2020, at any of the Mayo Clinic sites. We abstracted pertinent comorbid conditions such as age, sex, body mass index, Charlson Comorbidity Index variables, and treatments received. Factors associated with hospitalization and mortality were assessed in univariate and multivariate models., Results: A total of 7891 patients with confirmed COVID-19 infection with research authorization on file received care across the Mayo Clinic sites during the study period. Of these, 7217 patients were adults 18 years or older who were analyzed further. A total of 897 (11.4%) patients required hospitalization, and 354 (4.9%) received care in the intensive care unit (ICU). All hospitalized patients were reviewed by a COVID-19 Treatment Review Panel, and 77.5% (695 of 897) of inpatients received a COVID-19-directed therapy. Overall mortality was 1.2% (94 of 7891), with 7.1% (64 of 897) mortality in hospitalized patients and 11.3% (40 of 354) in patients requiring ICU care., Conclusion: Mayo Clinic outcomes of patients with COVID-19 infection in the ICU, hospital, and community compare favorably with those reported nationally. This likely reflects the impact of interprofessional multidisciplinary team evaluation, effective leveraging of clinical trials and available treatments, deployment of remote monitoring tools, and maintenance of adequate operating capacity to not require surge adjustments. These best practices can help guide other health care systems with the continuing response to the COVID-19 pandemic., (Copyright © 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.)